The abstract is read at the publisher; the summary is JClub's.
In the transplant-ineligible subgroup of newly diagnosed multiple myeloma (N=289), daratumumab plus bortezomib, lenalidomide, and dexamethasone achieved 60.4% MRD negativity (10^-5) versus 39.3% with VRd.
- Why it matters: Transplant-ineligible patients need regimens that deepen response and improve disease control, but tolerability limits options compared with transplant-eligible strategies.
- What they did: CEPHEUS phase III compared DVRd (n=144) versus VRd (n=145) in TIE NDMM, assessing MRD negativity (10^-5) and sustained MRD over time, alongside progression-free survival.
- The result: Sustained MRD negativity was higher with DVRd at ≥12 months (47.2% vs 28.3%) and ≥24 months (40.3% vs 22.8%), and PFS risk of progression or death was reduced (HR 0.51; P=.0003).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.